Cabergoline
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | DRUG-CABERGOLINE |
|---|---|
| Art | Arzneimittel |
| Aliase | DosierungКаберголін |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Erkrankungen | DIS-PITUITARY-ADENOMA |
| Quellen | SRC-NCCN-CNS-2025 |
Drug Facts
| Klasse | Dopamin D2-Rezeptoragonist, der aus der Mutterschaft stammt |
|---|---|
| Verfahren | Selective, high-affinity D2-dopamine receptor agonist with a long elimination half-life (~65 hours) permitting once- or twice-weekly oral dosing. Activates D2 receptors on pituitary lactotroph cells, suppressing prolactin synthesis/secretion and inducing lactotroph adenoma shrinkage in the majority of prolactinomas. First-line therapy for prolactinoma; superior prolactin-normalization rate, tumor-shrinkage rate, and tolerability compared with bromocriptine (older, less selective dopamine agonist). |
| Typische Dosierung | Start 0.25 mg PO twice weekly (or 0.5 mg PO once weekly); titrate by 0.25-0.5 mg/week increments no more often than every 4 weeks according to serum prolactin response, to a typical maintenance dose of 0.5-2 mg/week in divided doses twice weekly (occasionally higher, up to ~4.5 mg/week, in macroprolactinoma resistant to lower doses). Take with food to reduce nausea. Confirm exact titration schedule with treating endocrinology team. |
| Ukraine registriert | Wahr |
| NSZU erstattet | Falsch |
| Ukraine zuletzt überprüft | 2026-07-11 |
Anmerkungen
STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode-exempted, safe to merge as draft content, not published/verified clinical advice). Cabergoline is first-line therapy for prolactinoma per the Disease narrative (preferred over bromocriptine for prolactin-normalization rate, tumor shrinkage, and tolerability). Bromocriptine itself is not yet authored as a separate Drug entity in this KB — deferred as an open gap (see DIS-PITUITARY-ADENOMA proposal notes) since the narrative names it only as a comparator, not as a distinct recommended pathway.
Verwendet von
Therapieschema
REG-CABERGOLINE-PROLACTINOMA- Cabergoline für Prolaktinom (Dopaminagonist, First-Line)